Drug intelligence / Profile preview

OC137

Development stage: Preclinical
Lead developer: Nanomerics
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

OC137 is a preclinical-stage small molecule drug being developed by Nanomerics for the treatment of non-infectious posterior uveitis and other retinal diseases. It is formulated as an eye drop and utilizes Nanomerics' proprietary Molecular Envelope Technology (MET), which acts as a non-irritant ocular penetration enhancer to improve drug delivery to ocular tissues. The precise mechanism of action for OC137 has not been publicly disclosed. The drug is part of Nanomerics’ pipeline of topical ocular products targeting various eye diseases, with development focused on improving bioavailability and tissue targeting in the eye[1][2][3][5][6].

Brand names: Evysion
Other names: Rapamycin MET Eye Drops

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on OC137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC137.

Explore the full profile